.png "NovoCure Ltd (NASDAQ: NVCR)")
In a report released today, Larry Biegelsen from Wells Fargo maintained a Hold rating on NovoCure Ltd (NVCR). The company’s shares opened today at $53.71, close to its 52-week high of $54.73.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 17.6% and a 69.9% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Wright Medical Group, and Johnson & Johnson.
Currently, the analyst consensus on NovoCure Ltd is a Moderate Buy with an average price target of $51.
See today’s analyst top recommended stocks >>
Based on NovoCure Ltd’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.69 million. In comparison, last year the company had a GAAP net loss of $10.95 million.
Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.
